How to Contribute
The Atlas of Genetics and Cytogenetics in Oncology and Haematology does not publish research articles. The Atlas publishes reviews and "Case reports".
For complete Instructions, click here. In short, herein below:
ARTICLE TYPES
The Atlas publishes "cards" (on hematological diseases, solid tumors, cancer-prone
diseases, and genes), "deep insights", "case reports", and "educational items".
Please use the link "Submit Online" on the homepage to upload your manuscripts
following the instructions given.
The article categories that can be submitted to the
Atlas are the following:
- Hematological chromosomal
abnormalities
- Hematological single entity
-
Hematological free review
- Solid tumors- Simple pathologic
entity
- Solid tumors- Complex pathologic entity
-
Solid tumors- Free review
- Solid tumors- Summary
-
Cancer-prone diseases
- Genes in cancer
- Educational
items
- Case reports
- Deep
insights
1. Cards on hematology and solid tumors
For purpose of uniformity, the most recent World Health Organization (WHO) Classification of
Hematological Diseases and Tumors will be followed but adapted were appropriate for the Atlas.
There are different categories for submission in hematology and solid tumors. If
you are interested in contributing or updating a card already present in the Atlas, please
contact before our coordinator Dr. Ana E. Rodríguez, at anaerv@atlasgeneticsoncology.com, to
avoid duplications.
General TIPS:
o Definition: it is
not a properly an Abstract of the content. It can be used to report interesting review on the
topic.
o Please also supply key words.
o This is Atlas of Genetics, so pathologic findings must be summarized to
essential in the Si, however, an example of key immunohistochemistry picture are welcome as a
surrogate test for specific genetic marker.
o Using figures from other
published papers are allowed, but a permission from the publisher retaining the copyright is
required.
o Each contribution will be revised by editorial board
member(s).
o For a more detailed version, please check the “Instructions
for authors”.
1.1 Hematology cards
a) Hematological chromosomal
abnormalities
Describe chromosome abnormalities, structural and numeric, which have
been detected in a routine cytogenetic analysis
of patients with hematological disorders.
b) Hematological single
entity
Revision of entities included in the WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues. The revision incorporates clinical features, morphology,
immunophenotyping, cytogenetics, and molecular genetics to define disease entities of clinical
significance.
c) Hematological
free review
Revision about widespread topics in the hematological field related with
a single gene/fusion gene/chromosomal abnormalities which are in a group of different
hematological entities or a general topic involving one or more entities that have in common a
genetic marker.
Criteria of relevance of an entity:
- Chromosome
structural aberrations: found in at least 2 cases in a given cancer, or in only 1 case if the
hybrid gene is also described.
- Genes: fusion gene found in at least 1 cancer case, or gene
mutation, amplification or homozygous deletion found in a significant subset of cases in a given
cancer-type.
Subset of cases in a given cancer-type. with the same gene fusion
?(instead of hybrid gene ), mutation amplification or homozygous deletion (what about biallelic)
1.2 Solid tumors cards
a) Summary
When
possible, a summary of the ONLY genetic findings of a group of lesions having in
common the same cell of origin. Definition: it is not a properly an Abstract of the content. It
can be used to report interesting review on the group of lesions. with PMID dealing mainly with
recent reviews e.g. Soft tissue tumor: Adipocytic tumors; Kidney: pediatric mesenchymal
tumors; Vascular tumor of the bone. Genetic findings will be summarized very briefly in
Xcell Table for each lesions. Genetic information and mainly review article references are
provided for well-characterized cytogenetic/molecular tumors investigated in more than a single
case, with a few exceptions. Key immunohistochemistry data are welcome as a surrogate test for a
specific genetic marker.
The summary will be uploaded as Xcell, see the instructions, and
periodically updated when needed, according to new important papers appearing in the literature.
If a more comprehensive review for each entity/specific rearrangement is available in the Atlas,
such”links” it will be
highlighted.
b)
Single pathologic entity
Each pathological entity with already a detailed review
will be highlighted in each specific WHO list. Only the recent detailed review card will be
linked. If you are interested in contributing to summarize a single entity, not yet reported in
the Atlas, please contact BEFORE our coordinator Dr. Ana Rodriguez at
anaerv@atlasgeneticsoncology.com, so we will not have duplications. Please remember to
check WHO books for the correct official name of the entity and corresponding ICD-0 code, if you
cannot find please contact us.
This is Atlas of Genetics, so pathologic findings must be
summarized to essential, however, an example of a key immunohistochemistry picture is welcome as
a surrogate test for a specific genetic marker, or specific pathologic clue to recognize the
entity. Therefore, the readers can use such clues if they cannot use any genetic tools
c) Complex pathologic
entity
Genetic data are more complex in the most common tumors e.g. lung, breast,
prostate, and there is a need of additional tables and figures to describe the complexity of the
genetic markers (e.g. Gastro-intestinal tumors). Tables, figures, diagrams to summarize data are
welcome
d) Free
review
This template can be used in a very widespread of the topic in solid tumors
dealing
with:
o gene/rearrangement promiscuity in a group of different tumors e.g.
o Specific treatment of any genetic marker in one or more
entity(ies)
o Immunohistochemistry for genetic
markers
o Specific technology for picking up a genetic
marker
o Any general topic involving an entity or more entities having in common
genetic marker
It will not have a specific ICD-0 code and you can use as you what the free
space with tables, figures, diagrams. See details out to upload your contribution in the
instructions for authors.
Definition: in such cases, it will be more as Abstract, a
summary of the topic. Please also supply key words.
2. Cancer-prone disease cards
Significant aggregation of genetic disorders in which inherited genetic mutations in one or more
genes predisposes the affected individuals to the early onset development of cancers
3. Genes in cancer cards
Please, use Hugo names (HGNC official nomenclature), with the usual name in brackets if
necessary: avoid the most confusing "p21", erk", or "mek".
You will find official gene
names at https://www.genenames.org/.
4. Deep insights
These papers do not follow the above-mentioned patterns; they are written as traditional papers,
made of paragraphs with headings, at the author's convenience.
5. Case Reports
This section is dedicated to case reports dealing with new as well as recurrent -but rare- chromosomes abnormalities in leukemias, lymphomas, and solid tumors.
Case Reports serve important purposes: from communicating the discovery of a new chromosome
aberration to confirming a recurrent, but rare, abnormality. They can also be a mean to
providing new clinical and therapeutic data concerning recurrent chromosome abnormalities. A
single laboratory may see a new translocation associated with a neoplasm only once.
Communicating this finding to others can be useful to discover more of such cases and provide
the platform for larger studies, which could lead to the discovery of new genes involved in the
development and/or progression of various neoplasms. When essential information is provided,
case reports have the potential to be highly readable and as such have a significant impact on
subsequent clinical research.
IMPORTANT INSTRUCTIONS TO AUTHORS:
Authors should, in a couple of sentences,
describe why the submitted case report should be considered for acceptance in the Atlas.
1.
Cases of interest shall be:
a) new (previously unreported);
b) recurrent (i.e. previously
described in at least 1 case; maximum 3 cases);
c) additional cases as part of a large
series may be accepted only if they provide additional clinical and therapeutic
information;
d) Contain well-documented clinics and laboratory findings.
2. Provide
iconography relating to the chromosome aberration(s). If FISH or microarray was performed,
provide those images for the reviewers and for the publication: in NO case will a case report be
accepted without the karyotype and/or FISH and/or microarray (if performed).
The informed
consent is compulsory. A template of an informed consent can be found here.
6. Educational Items
Must be didactic, give full information and be accompanied with iconography.
Please, contact us before undertaking any work, to avoid double (conflicting) reports.
ICONOGRAPHY solely
It is possible to send only images (i e: karyotype, FISH analysis, etc) accompanied by a
legend. We are still working how to present such items and link to the existing cards in the
Atlas. More details will be available soon.
Conflicts of Interest
Authors must state explicitly whether potential conflicts do or do not exist. Reviewers must
disclose to editors any conflicts of interest that could bias their opinions of the manuscript.
The editor and the editorial board members must disclose any potential conflict. See Editorial
Ethics.
Privacy and Confidentiality – Iconography
Patients have a right to privacy. Identifying details should be omitted. If complete anonymity is difficult to achieve, informed consent should be obtained. See Editorial Ethics.
Creative Commons
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France License.
